FindTrial
Sign In

To show that reverse Hybrid therapy is as efficacious in eradication of helicobacter pylori infection as concomitant therapy with fewer adverse events and better compliance

Concomitant Versus reverse hybrid therapy for the eradication of helicobacter pylori infection- an open-label randomised control trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/11/038336
Enrollment
148
Registered
2021-11-30
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K27- Peptic ulcer, site unspecified

Interventions

Intervention1: Concomitant and reverse hybrid eradication regime: One group will receive concomitant therapy and the other will receive reverse hybrid therapy and their eradication rate, adverse event

Sponsors

JIPMER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Who have undergone upper gastrointestinal endoscopy in department of surgery with helicobacter pylori infection and need eradication

Exclusion criteria

Exclusion criteria: Patients who have received previous eradication therapy Patients who have had previous history of allergy to any antibiotic of our study Patients who have undergone previous gastric Tommy Patients with coexisting severe concomitant illness Pregnant or lactating women Patients who used antibiotics in the previous 4 weeks Patients diagnosed with any malignancies Patients with portal gastropathy

Design outcomes

Primary

MeasureTime frame
To compare efficacy of concomitant and reverse hybrid therapy in eradication of helicobacter pylori infection Also to compare compliance and adverse effects of concomitant and reverse hybrid therapyTimepoint: Patients with ulcer disease will undergo a rapid urease test and patients with non ulcer disease will undergo a stool antigen test at end of 6 weeks from initiation of therapy to confirm eradication—

Secondary

MeasureTime frame
To compare efficacy of concomitant and reverse hybrid therapy in eradication of helicobacter pylori infection Also to compare compliance and adverse effects of concomitant and reverse hybrid therapyTimepoint: Efficacy is compared by testing for eradication of helicobacter pylori infection by end of 6 weeks from initiation of therapy—

Countries

India

Contacts

Public ContactRatul DK

JIPMER

drvikramkate@gmail.com9843058013

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026